arrow
M

Masahiro Iwasaku

Kyoto Prefectural University of Medicine
H指数:24
被引数:1,903

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Health care contact days after second-line systemic therapy in patients with advanced non-small cell lung cancer in Japan with or without subsequent systemic therapy

日本接受二线全身治疗后的晚期非小细胞肺癌患者,在有无后续全身治疗情况下的医疗接触天数

2026-10-080
PRE
Identification of Hidden Cachexia Subgroup in PD-L1-High NSCLC: Comparative Analysis of the AWGC vs. Fearon Criteria

识别PD-L1高表达非小细胞肺癌中隐藏恶病质亚组:AWGC与Fearon标准的比较分析

2026-04-120
OAAI
Clinical impact of cancer cachexia on the outcome of patients with non-small cell lung cancer with PD-L1 tumor proportion scores of ≥50% receiving pembrolizumab monotherapy versus immune checkpoint inhibitor with chemotherapy
2024-12-160
OAAI
Depth of response and treatment outcomes of immune checkpoint inhibitor-based therapy in patients with advanced non-small cell lung cancer and high PD-L1 expression: An exploratory analysis of retrospective multicenter cohort
2024-08-210
PRE
CYFRA 21-1 predicts efficacy of combined chemoimmunotherapy in patients with advanced non-small cell lung cancer: a prospective observational study
2024-08-010
OAAI
Unraveling the influence of TTF-1 expression on immunotherapy outcomes in PD-L1-high non-squamous NSCLC: a retrospective multicenter study
2024-07-150
OAAI
Comparing Three Different Anti-Programmed Death-Ligand 1 Antibodies in Immunohistochemical Evaluation of Combined Chemoimmunotherapy Response in Patients With NSCLC: A Prospective Study
2024-03-010
OA
Prognostic impact of clinical factors for immune checkpoint inhibitor with or without chemotherapy in older patients with non-small cell lung cancer and PD-L1 TPS ≥ 50%

免疫检查点抑制剂联合化疗对TPS ≥ 50% 的老年非小细胞肺癌PD-L1预后的影响

2024-02-232
OAAI
Chemoimmunotherapy Versus Pembrolizumab as a First-Line Treatment for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression: Focus on the Role of Performance Status
2023-10-302
PRE
Clinical impact of proton pump inhibitor on the therapeutic outcome of non-small cell lung cancer patients with PD-L1 TPS I50% receiving pembrolizumab monotherapy versus immune checkpoint inhibitor plus chemotherapy: A retrospective multicenter cohort study
2023-10-010
OA